Takeda Pharmaceuticals and Shire completed a deal pursuant to which Takeda acquired the entire issued and to be issued ordinary share capital of Shire. Under the terms of the acquisition, each Shire shareholder received $30.33 in cash for each Shire share and either 0.839 new Takeda shares or 1.678 Takeda ADSs. "Over the last 30 years, Shire has become the global leader in treating rare diseases, delivering innovative products that transform patients’ lives. With this combination, Shire helps create an even stronger biopharmaceutical company, with a robust R&D pipeline and expanded global footprint. We are proud of what Shire has become and are grateful to all Shire employees for their contributions. We firmly believe that this combination recognizes the strong growth potential of our leading products and innovative pipeline and is in the best interests of our shareholders, our patients and the communities we serve," Susan Kilsby, Shire chairman.